From the perspective of a lipid specialist, especially in light of the associated all-cause mortality reductions reported in ODYSSEY Outcomes, how should the clinician be thinking about PCSK9 inhibitors as a tool in their day-to-day practice?

From the perspective of a lipid specialist, especially in light of the associated all-cause mortality reductions reported in ODYSSEY Outcomes, how should the clinician be thinking about PCSK9 inhibitors as a tool in their day-to-day practice?

CLICK HERE FOR CME CREDIT

From the perspective of a lipid specialist, especially in light of the associated all-cause mortality reductions reported in ODYSSEY Outcomes, how should the clinician be thinking about PCSK9 inhibitors as a tool in their day-to-day practice?

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Lipidologist and Atherosclerosis Specialist's Perspective

Presenter

Erik S.G Stroes, MD, PhD

Erik S.G Stroes, MD, PhD

Professor Department of Vascular Medicine Academic Medical Center Amsterdam, The Netherlands